Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) had its target price boosted by research analysts at HC Wainwright from $15.00 to $20.00 in a report issued on Wednesday, MarketBeat.com reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price target suggests a potential upside of 204.88% from the company's previous close. HC Wainwright also issued estimates for Abeona Therapeutics' Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at ($0.83) EPS, Q1 2026 earnings at $0.10 EPS, Q2 2026 earnings at $0.11 EPS, Q3 2026 earnings at $0.16 EPS, Q4 2026 earnings at $0.19 EPS and FY2026 earnings at $0.57 EPS.
Other equities analysts have also recently issued reports about the stock. Oppenheimer started coverage on shares of Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 target price for the company. StockNews.com upgraded shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $18.75.
Read Our Latest Report on ABEO
Abeona Therapeutics Price Performance
Shares of NASDAQ ABEO traded down $0.31 during trading on Wednesday, reaching $6.56. The company had a trading volume of 1,786,940 shares, compared to its average volume of 559,196. The business's 50 day moving average price is $5.09 and its 200-day moving average price is $5.61. The stock has a market cap of $320.13 million, a PE ratio of -2.44 and a beta of 1.68. Abeona Therapeutics has a 52 week low of $3.93 and a 52 week high of $7.32. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.19. Analysts expect that Abeona Therapeutics will post -1.16 earnings per share for the current year.
Insider Buying and Selling at Abeona Therapeutics
In other Abeona Therapeutics news, CEO Vishwas Seshadri sold 25,000 shares of the business's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $4.78, for a total transaction of $119,500.00. Following the sale, the chief executive officer now directly owns 1,355,322 shares of the company's stock, valued at $6,478,439.16. The trade was a 1.81 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 5.40% of the company's stock.
Hedge Funds Weigh In On Abeona Therapeutics
A number of hedge funds have recently made changes to their positions in ABEO. Twinbeech Capital LP bought a new position in shares of Abeona Therapeutics in the 4th quarter worth about $58,000. Squarepoint Ops LLC bought a new position in shares of Abeona Therapeutics in the fourth quarter valued at approximately $67,000. Cannon Global Investment Management LLC purchased a new stake in Abeona Therapeutics in the 1st quarter valued at about $67,000. Jane Street Group LLC bought a new position in shares of Abeona Therapeutics during the 3rd quarter worth approximately $84,000. Finally, Oxford Asset Management LLP purchased a new position in shares of Abeona Therapeutics in the 4th quarter worth approximately $118,000. 80.56% of the stock is currently owned by institutional investors.
About Abeona Therapeutics
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Stories
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
